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BACKGROUND: Multiple clinical risk factors and genetic profiles have been demonstrated to predict progression of non-muscle invasive
bladder cancer; however, no easily clinical applicable gene signature has been developed to predict disease progression independent
of disease stage and grade.
METHODS: We measured the intra-patient variation of an 88-gene progression signature using 39 metachronous tumours from 17
patients. For delineation of the optimal quantitative reverse transcriptase PCR panel of markers, we used 115 tumour samples from
patients in Denmark, Sweden, UK and Spain.
RESULTS: Analysis of intra-patient variation of the molecular markers showed 71% similar classification results. A final panel of 12 genes
was selected, showing significant correlation with outcome. In multivariate Cox regression analysis, we found that the 12-gene
signature was an independent prognostic factor (hazard ratio¼ 7.4 (95% confidence interval: 3.4–15.9), Po0.001) when adjusting for
stage, grade and treatment. Independent validation of the 12-gene panel and the determined cut-off values is needed and ongoing.
CONCLUSION: Intra-patient marker variation in metachronous tumours is present. Therefore, to increase test sensitivity, it may be
necessary to test several metachronous tumours from a patient’s disease course. A PCR-based 12-gene signature significantly predicts
disease progression in patients with non-muscle invasive bladder cancer.
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A total of 70 530 new bladder cancer cases and 14 680 deaths were
estimated in the United States alone in 2010 (Jemal et al, 2010).
About 75% of patients present with non-muscle invasive tumours
were mostly treated with a local, organ-sparing approach. The
remaining 25% of patients are initially diagnosed with muscle
invasive cancers, most often requiring immediate and more radical
treatment. More than 60% of patients with non-muscle invasive
bladder cancer experience tumour recurrences and around 20% of
the patients develop disease progression to a muscle invasive
bladder cancer (Millan-Rodriguez et al, 2000; Sylvester et al, 2006).
Clinical risk factors associated with a high risk of disease
progression to a muscle invasive cancer include deep invasion of
the lamina propria, high-grade tumour, large tumour size,
concurrent carcinoma in situ (CIS), tumour multiplicity and
recurrence of high-risk non-muscle invasive tumours (Hermann
et al, 1998). The clinical risk factors cannot predict the individual
disease course accurately, and currently no molecular markers are
available for clinical use for predicting tumour recurrence or later
disease progression (Ehdaie and Theodorescu, 2008).
Several microarray-based gene-expression signatures for diag-
nosis or prognosis have been identified in many cancers, including
bladder cancer (Rosenwald et al, 2002; van de Vijver et al, 2002;
van’t Veer et al, 2002; Ramaswamy et al, 2003; Dyrskjot et al, 2007a).
Although clinically applicable, it may, however, be easier to
implement tests for clinical use when simpler, cheaper and more
sensitive methods are being used. We have previously identified a
molecular gene-expression signature for predicting disease progres-
sion in patients with non-muscle invasive bladder cancer (Dyrskjot
et al, 2005). The progression signature was validated successfully in
a retrospective study that included 294 patients from five different
countries. The molecular signature was significantly correlated with
progression-free survival (Po0.001) and it was shown to be
significantly associated with disease progression after adjustment
for age, sex, stage, grade and treatment (hazard ratio (HR)¼ 2.3;
P¼ 0.007) (Dyrskjot et al, 2007b). One of the objectives to be
addressed before clinical implementation is intra-patient variation
of the molecular signature when applied to multiple tumours from
the same patient. How often do we need to test in each patient?
Another objective is the generation of a clinically applicable gene
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signature, and this requires transferring the markers from the
microarray platform to a robust PCR-based platform.
Here we address the intra-patient variation of the original
88-gene signature by analysing 39 metachronous tumours from 17
patients. We combined this analysis with mutation screening of the
genes frequently mutated in bladder cancer: FGFR3 (16–74%
mutated – dependent on stage), PIK3CA (13–27% mutated) and
RAS family (NRAS, KRAS and HRAS; 13% mutated) (Billerey et al,
2001; Kompier et al, 2010). Then, we describe the transfer of the
optimal signature genes from the microarray platform, plus
additional prognostic genes identified, to a PCR platform for
easier clinical implementation of the molecular classifier.
MATERIALS AND METHODS
Patients and tumour samples
The majority of the patients and tumour samples used in this work
were used previously for validating our microarray-based 88-gene
progression signature (Dyrskjot et al, 2007b). Urothelial carcino-
mas were taken from patients that were operated in the years 1987–
2000 in hospitals in Denmark, Sweden, Spain and England and frozen
immediately at  80 1C. All patients were followed according to the
valid guidelines at patient inclusion time. Informed written consent
was obtained from all patients, and research protocols were approved
by the institutional review boards or ethical committees in all involved
countries. Diagnostic pathology slides were reevaluated according to
the World Health Organisation (WHO) 2004 guidelines. However, for
19 out of the 115 patients, it was not possible to acquire the diagnostic
sections for review and consequently the original grading was
translated into the WHO 2004 grading system (G1þG2¼ low grade,
G3þG4¼ high grade), although this translation is too simplified in
some cases. Progression-free survival time was recorded from
sampling visit and censored at the time of the last control cystoscopy
or at cystectomy. Progression of the disease was defined as (i)
histologically confirmed invasion into the bladder muscle or (ii) cases
where the patient died of bladder cancer without a verified
progression event as described above (n¼ 5). In case of bladder
cancer death, survival was recorded from the date at which tissue was
collected and until the last annotation of the patient being alive.
RNA extraction and cDNA generation
Total RNA was extracted from the Danish, and English samples
using a standard Trizol RNA extraction method (Invitrogen,
Carlsbad, CA, USA). Total RNA from Swedish and Spanish samples
was extracted using RNeasy mini kit (Qiagen, Valencia, CA, USA).
All RNA was quality controlled using an Agilent Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA) (criteria: 28S/18S 41
and RIN 45). In all, 1mg of total RNA was DNAse-treated using
DNase I Amplification Grade (Invitrogen) to avoid amplification of
genomic DNA. Adequate DNAse treatment was verified in all samples
by quantitative reverse transcriptase PCR (qRT–PCR) using intron
spanning GAPDH primers. The DNAse-treated total RNA was
converted to cDNA using oligo (dT) priming and SuperScript II
Reverse Transcriptase (Invitrogen) according to the standard protocols.
Initial selection of 96 genes for analysis
Genes were selected using two different approaches. First, genes
were selected from the prognostic gene signatures published
previously (Dyrskjot et al, 2007b). Second, we reanalysed previously
published microarray data (Dyrskjot et al, 2003, 2004; Aaboe et al,
2005; Dyrskjot et al, 2005). For each gene, the microarray
hybridisation intensity was plotted against progression-free survival
of each patient and linear and quadratic regression equations were
computed. The noise was calculated as a function of squared
deviations of each patient from the squared regression line. Then,
the ratio of linear regression coefficient to noise was calculated for
each gene and used as a measure of ‘signal-to-noise’ ratio. Genes
were then selected based on ‘signal-to-noise’ performance. The two
different approaches showed large overlap in genes selected, and we
selected those showing the best performance with each approach.
Primer design and PCR assays
Microarray layout files were used to map the Affymetrix (Santa
Clara, CA, USA) probe sets to mRNA sequences and this region
was then used to design primers for qRT–PCR assays. For each of
the selected candidate genes, we designed three primer pairs using
PRIMER3 software (Rozen and Skaletsky, 2000). For sensitivity
measures, we used 1, 0.1 and 0.01 ng cDNA template. A minimum
of two replicates had to amplify at a particular concentration to
qualify as the limit of sensitivity. Furthermore, the threshold cycle
(Ct) spread between the replicates at this concentration had to be
less than one cycle. Specificity measures were performed using no
template control measurements where Ct should be 440. The
qRT–PCR using the final primer set was carried out using a
7900HT Fast Real-Time PCR System (Life Technologies, Carlsbad,
CA, USA) in 384-well plates. A total of 115 tumour samples were
analysed. All reactions were performed in triplicate in 10-ml
volumes using SYBR Green PCR Master Mix (Life Technologies)
and the standard protocols were applied.
Normalisation, optimal 12-gene set selection and
molecular classification
To identify the best-performing candidate genes, we normalised
data using average total-patient Ct values and using an average
global total. Classifier genes were selected based on different
statistical methods applied to normalised Ct values and clinical
outcome (progression vs no progression): Pearson’s correlation,
Po0.01; Wilcoxon signed-rank test, Po0.01; Cox regression
analysis, Po0.01; and area under curve (AUC) from receiver
operating characteristics (ROCs), AUC40.65. Classifier genes with
high correlation were not excluded from the final signature.
Computation of risk scores utilised non-normalised Ct values
based on the formula: average (Ct (genes downregulated in
progressing tumours) average (Ct (genes upregulated in pro-
gressing tumours)). This approach eliminated the requirement of
using normalised Ct values. The optimal cut-off value (risk score
with the highest accuracy) and the 90% sensitivity cut-off value were
identified from ROC curves, and risk scores were then dichotomised
based on these two different cut-off values. Dichotomised signature
values were used to classify samples as either high or low risk of
progression (1¼ high risk and 0¼ low risk).
Affymetrix Exon ST 1.0 array analysis and classifier construction
Affymetrix human Exon ST 1.0 arrays were used for measuring
gene expression in 39 tumours from 17 patients as described
previously (Thorsen et al, 2008). itPLIER normalisation and
generation of gene-expression measures were performed in
GeneSpring GX 10.0 with no baseline adjustment. To identify the
original 88-gene signature, we used BLASTN (NCBI) against
human RefSeq RNA sequences for all original probe sequences to
updated Gene Symbol annotation. Following, we used the Gene
Symbols for identifying the corresponding probe sets on the Exon
ST 1.0 arrays. We preferentially selected ‘core’ probe set with the
highest number of exon clusters. A maximum likelihood classifier
was constructed as described previously (Dyrskjot et al, 2003)
using 10 tumours that were originally used for building the
classifier and for testing the 39 independent tumour samples.
Mutation analysis
Mutation analysis of the genes FGFR3, PIK3CA, NRAS, KRAS and
HRAS was performed essentially as described previously (Kompier
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et al, 2010) for 36 out of the 39 tumours samples analysed on the
Exon ST 1.0 microarray platform.
Statistical procedures
We used STATA 10.0 (Stata Corporation, College Station, TX,
USA) for statistical analysis. Variables with a P-value o0.05 in
univariate analysis were included in multivariate analysis. The
assumptions of proportional hazards were verified.
RESULTS
Intra-patient variation
We set out to analyse the progression signature in 39 metachro-
nous bladder tumours from 17 patients by Exon ST 1.0 microarray
analysis to measure the intra-patient variation of the signature.
The mutational status of the samples was also analysed to obtain
an indication of the genetic relatedness of the metachronous
tumours. The classification result and mutation analysis of the
genes FGFR3, PIK3CA, NRAS, KRAS and HRAS are shown in
Table 1. NRAS, HRAS and KRAS were not mutated in any of the
tumours analysed. Multiple tumours from 12 patients (71%)
showed similar intra-patient classification results, however, in
another five cases the intra-patient analysis results were dissimilar;
two of these patients showed variation in mutation status of the
FGFR3 gene, indicating differences in tumour clonality. All other
tumours showed similar mutation status.
Patient and marker selection
Initially, we selected 96 genes associated with disease aggressive-
ness from published gene signatures (38 genes) and from
reanalysis of microarray data (58 genes). Following primer design
and initial validation of primer sensitivity and specificity, we
decreased the number of interesting genes to 35 in total (Table 2).
We performed qRT–PCR measurements of the 35 genes using 115
tumour samples from patients in Denmark, Sweden, UK and
Spain. Previously, 102 of these tumours were used for validating
our microarray-based 88-gene signature. Patients with no disease
progression were followed for a minimum of 60 months (the
median follow-up time was 88 months). Clinical and histopatho-
logical characteristics for all patients are shown in Table 3.
12-gene PCR signature
We selected the genes for inclusion in the optimal PCR signature
by comparing normalised Ct values and clinical outcome using
Table 1 Intra-patient variation based on 88-gene classifier results and mutation analysis
Mutation analysis
Sample Stage Gradea 88-gene classifierb FGFR3 PIK3CA NRAS HRAS KRAS
532-12 Ta II 1 S249C WT WT WT WT
532-15 Ta II 1 S249C WT WT WT WT
1888-1 Ta II 1 S249C WT WT WT WT
1888-2 Ta II 1 S249C WT WT WT WT
1841-4 Ta II 1 S249C WT WT WT WT
1841-6 Ta II 1 S249C WT WT WT WT
1926-1 Ta II 1 G372C WT WT WT WT
1926-4 Ta II 1 G372C WT WT WT WT
1926-6 Ta II 1 G372C WT WT WT WT
1657-1 Ta I 1 S249C WT WT WT WT
1657-3 Ta II 1 S249C WT WT WT WT
1899-2 Ta III 1 G372C WT WT WT WT
1899-3 T2–4 III 2c WT WT WT WT WT
1992-1 Ta I 2 S249C WT WT WT WT
1992-3 T1 II 1 S249C WT WT WT WT
2010-1 T1 III 2 S249C WT WT WT WT
2010-4 T2–4 III 2 S249C WT WT WT WT
1375-1 T1 II 1 S249C E545K WT WT WT
1375-7 Ta II 1 S249C E545K WT WT WT
1735-1 T1 III 2 WT WT WT WT WT
1735-4 Ta II 2 WT WT WT WT WT
1702-1 Ta I 1 S249C WT WT WT WT
1702-7 Ta II 1 S249C WT WT WT WT
1702-11 Ta I 1 S249C WT WT WT WT
1790-1 Ta I 1 Y375C WT WT WT WT
1790-3 Ta II 1 Y375C WT WT WT WT
562-3 Ta I 2 Y375C WT WT WT WT
562-5 Ta II 2 Y375C WT WT WT WT
1521-1 Ta I 1 S249C WT WT WT WT
1521-6 Ta I 1 S249C WT WT WT WT
1521-10 T1 II 1 — — — — —
1732-1 T1 II 2 — — — — —
1732-11 Ta II 1 S249C WT WT WT WT
1732-12 T2–4 III 2 — — — — —
1829-1 Ta II 1 S249C WT WT WT WT
1829-2 Ta II 2 S249C WT WT WT WT
1829-3 T1 III 1 S249C WT WT WT WT
2363-1 T1 III 1 S249C WT WT WT WT
2363-2 T2–4 III 2 WT WT WT WT WT
aBergkvist grading. b1¼ classified as a non-progressing tumour and 2¼ classified as a progressing tumour. cLess than 5% difference in classification distance between the two
classes. Bold denotes intra-patient differences in 88-gene classifier results or in mutation status.
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Pearson’s correlations, ROC analysis, Wilcoxon signed-rank tests
and Cox regression analysis. Using these different statistical
methods in a combined approach, we selected 12 genes that
showed significant correlation with outcome (see Figure 1A and
Table 4); seven were upregulated in progressing tumours
compared with non-progressing tumours (KPNA2, BIRC5,
UBE2C*, CDC25B, COL4A1*, MSN and COL18A1*) and five were
downregulated in progressing tumours compared with non-
progressing tumours (COL4A3BP*, MBNL2, NEK1*, FABP4 and
SKAP2*). The six genes marked with an asterisk were not
previously included in our gene signature for outcome prediction.
Selecting fewer genes using more stringent selection criteria did
not result in increased classification performance (results not
shown). A schematic representation of the steps involved in
reaching the final 12-gene PCR signature is shown in Figure 2.
Molecular classification
Molecular prediction of outcome was carried out for all 115
patients based on the generated PCR risk scores. An optimal cut-
off value (0.79; 76% sensitivity and 86% specificity) was identified
using ROC analysis (Figure 1B) and the dichotomised scores
showed significant correlation with progression-free survival
(Po0.0001, log-rank test; Figure 1C). In multivariate Cox
regression analysis, we found that the 12-gene signature was an
independent prognostic variable (HR¼ 7.4 (95% confidence
interval: 3.4–15.9), Po0.001) when adjusting for stage, grade and
BCG/MMC treatment (Table 5). When only including high-risk
patients in the analysis (i.e., stage T1, high grade or concomitant
Table 2 Primer sequences for the 35 candidate genes
Gene targeta Upstream primer sequence 50–30 Downstream primer sequence 50–30 Gene selectionb
ADAM10 50-CAGTATTACTTATGGGAATTGCTCTG-30 50-TTGGATTACTACTTGGAGTATGAACAC-30 1
AURKB 50-TTTGCTATGAGCTGCTGGTG-30 50-ACTTTAGGTCCACCTTGACGATG-30 1
BIRC5 50-CTGAAGTCTGGCGTAAGATGATG-30 50-GAAGCTGTAACAATCCACCCTG-30 1
C10orf58 50-GTAAACCTACTTTCTGTTCTGGAAGC-30 50-TTTTCTCTGAGGCCAAAGTCTG-30 1
CDC20 50-AGTCCAATGTCCTGGCAACAG-30 50-CCAGAGCACACATTCCAGATG-30 1
CDC25B 50-GATGGAAGGTTGGATGGATG-30 50-ACCTGGTTTGGGTATGCAAG-30 1
COL4A1 50-CTGCCTGGAGGAGTTTAGAAGTG-30 50-CTGTAAGCGTTTGCGTAGTAATTG-30 1
FABP4 50-AGAGAAAACGAGAGGATGATAAACTG-30 50-CTTATGCTCTCTCATAAACTCTCGTG-30 1
IGF2 50-CATCGTTGAGGAGTGCTGTTTC-30 50-GGGTAGCACAGTACGTCTCCAG-30 1
ITGB4 50-CATCATCCCTGACATCCCTATC-30 50-GTAGAACGTCATCGCTGTACATAAG-30 1
KPNA2 50-GCAGATTTTAAGACACAAAAGGAAG-30 50-AAGGTACACAATCTGTTCAACTGTTC-30 1
MAT2B 50-TTGTCTAAAGAAACTAAAGGGCAGTC-30 50-AGTTTAGCCAGGACAAACAAAATG-30 1
MBNL2 50-ACTTCATCCAGTGCCCACTTTC-30 50-GGGGTTACAGGTGCTAGGTAAGG-30 1
MCM7 50-GAGATGTCAAAGGACTCTCTTCTAGG-30 50-GCAAATATCACATCTGCTGGTC-30 1
MSN 50-CCTGACCTTGAGGAGTCTTGTG-30 50-AATATAGGACATATCACCAAGTGAGC-30 1
PPP2R5C 50-GTACTACATTGAAAATAAACCGGTGAC-30 50-TACATTTTGGAAAGAGTGAAGATGC-30 1
TCF4 50-GAATCACATGGGACAGATGTAAAAG-30 50-AATACAGCTGTTAAGGAAGTGGTCTC-30 1
ACTA2 50-GTCTCTAGCACACAACTGTGAATGTC-30 50-CTAGGAATGATTTGGAAAAGAACTG-30 2
CDH5 50-AAACAATTCCTGTAACCTTCTATTTTC-30 50-CTTGTCATGCACCAGTTTGG-30 2
CDKN3 50-ATCTCTACCAGCAATGTGGAATTATC-30 50-CTATGTCAGGAGTCCCTCCATC-30 2
COL18A1 50-GGGCTGGTTCTGTAATTGTGTG-30 50-AAAAGGTCACTTTTATTTGCCTGTC-30 2
COL4A3BP 50-TTTCTGTGGATCATGACAGTGC-30 50-CAAGGTTTGACAAATCATAGCAAC-30 2
CPS1 50-GGAAGTAAGGTTCATTCCCTTAAGAC-30 50-CCTTACAGTGGGTGGAATTAATAGTG-30 2
DCTD 50-TGTGCCCCTTCTCTTTAATCTC-30 50-GAAAGCCTTTTCTCAACACAGG-30 2
IER2 50-CTTGCCAGGGAGTTTCTGAG-30 50-ATTTCTAACAAAACGCCAGGTAGAC-30 2
LBR 50-ATCAGAAAGTGGTGGCGTTTTC-30 50-TTACCAGGGAAAGAATTTAATGTCC-30 2
LGALS1 50-CTGAATCTCAAACCTGGAGAGTG-30 50-GGTTCAGCACGAAGCTCTTAGC-30 2
NEK1 50-CTAAAAGACCAGCTTCAGGACAAAAC-30 50-CTAAAGGTATTCCATATTTAGCGGC-30 2
NR1H3 50-GGAATTCATCAACCCCATCTTC-30 50-GATAGCAATGAGCAAGGCAAAC-30 2
PEA15 50-ACTCCTTATATTGCTGTGAGATTGC-30 50-ACCTTTATTCCGGGTTAGAACAAG-30 2
SKAP2 50-TGGAGATGTATGATATTTGAGAGTCC-30 50-CTAAATCCAAAGCATTTGCAGAC-30 2
SDC1 50-AGACACCTTGGACATCCTCCTC-30 50-TAAGCAAGTAAGTGCAGGAGCC-30 2
SEC14L1 50-TGTTTCTACCTTTAGTACCTTGCCAC-30 50-AGTACTAAGAAATGGGAAATGACAGC-30 2
UBE2C 50-TCTAGGAGAACCCAACATTGATAGTC-30 50-TCTTGCAGGTACTTCTTAAAAGCTG-30 2
WNT2B 50-ATAAGAAACTGTGCAAGCTCCC-30 50-TCTACTCTCCCTTCAAATCTCCAG-30 2
aGenes in bold are included in the final 12-gene signature. bGene selection method: 1¼ from previously published gene signatures and 2¼ from reanalysis of gene-expression data.
Table 3 Clinical and histopathological characteristics for all 115 patients
Number of patients 115
Median follow-up time in months for all patients (range) 69 (1–216)
Median follow-up time in months for progressing patients (range) 20 (1–123)
Median follow-up time in months for non-progressing patients (range) 88 (61–216)
Median age (range) 70 (33–88)
Male–female ratio 4.9
Stage
Ta 62 (54%)
T1 53 (46%)
Grading (WHO 2004)
PUNLMP 17 (15%)
Low grade 33 (29%)
High grade 65 (56%)
Concomitant CIS
Yes 19 (17%)
No 50 (43%)
Unspecified 46 (40%)
Adjuvant therapy (BCG or MMC)
Yes 34 (30%)
No 81 (70%)
Number of progression events to stage T2–4 bladder cancer
Ta 13 (30%)
T1 33 (70%)
Abbreviations: BCG¼ bacillus Calmette-Guerin; CIS¼ concurrent carcinoma in situ;
MMC¼mitomycin C; WHO¼World Health Organisation.
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CIS), we also found a significant correlation with progression-free
survival (Po0.0001, log-rank test; Figure 1D). Similarly, when
including only the low-risk subpopulation in the analysis, we also
found a significant correlation with progression-free survival
(P¼ 0.0002, log-rank test; Figure 1E). We calculated the predictive
accuracy using Harrell’s C to 73% for clinical variables only, 75% for
the 12-gene signature, and this number was raised to 82% when
including clinical variables and the 12-gene signature in the model.
Consequently, accurate prediction of progression is increased when
including the molecular markers. When changing the cut-off value to
 0.17 to ensure a 90% sensitivity (and 61% specificity) of the test,
we also observed significant correlations with outcome for the entire
patient cohort and the risk subgroups as shown in Figure 1F–H.
DISCUSSION
Identification of highly sensitive and specific biomarkers for
prediction of outcome for patients with non-muscle invasive
bladder tumours is of utmost clinical importance. Here we report
the required step in clinical implementation of gene-expression
signatures; the generation of a 12-gene signature for disease
progression using qRT–PCR. We showed that the final 12-gene
signature correlated highly significantly with outcome, and showed
independent prognostic value when stratifying for stage, grade and
treatment. Furthermore, by mutational analysis of genes frequently
mutated in bladder cancer (FGFR3, PIK3CA and RAS family genes)
combined with microarray-based analysis of an earlier reported
88-gene prognostic signature, we showed that intra-patient
reproducibility and switch in tumour clonality may indicate that
the 12-gene PCR signature analysis of several recurrent tumours is
necessary in each single patient.
The analysis of intra-patient reproducibility of the microarray-
based 88-gene molecular signature showed that in most cases
(71%), identical classifications were obtained. In two of the five
cases where divergent results were obtained, we also observed
differences in the mutation status of FGFR3, indicating that
the tumours may have arisen from different subclones.
C
KPNA2
BIRC5
UBE2C*
CDC25B
COL4A1*
MSN
COL18A1*
COL4A3BP*
MBNL2
NEK1*
FABP4
SKAP2*
A B
D E
Receiver operating characteristic
0.00
0.25
0.50
0.75
1.00
Se
ns
itiv
ity
0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.848
Progression
Stage
Grade
12-gene signature
Low-risk patients – optimal cut-off value
0.00
0.25
0.50
0.75
1.00
8 4 0 0
39 37 11 0
Number at risk
0 50 100 150
Analysis time
Low-risk signature
High-risk signature
P=0.0002
High-risk patients – optimal cut-off value
0.00
0.25
0.50
0.75
1.00
36 11 2 0 0
32 27 10 1 1
Number at risk
0 50 100 150 200
Analysis time
Low-risk signature
High-risk signature
P<0.0001
Optimal cut-off value
All patients – optimal cut-off value
Low-risk signature
High-risk signature
0.00
0.25
0.50
0.75
1.00
44 15 2 0 0
71 64 21 1 1
Number at risk
0 50 100 150 200
Analysis time
P<0.0001
0.00
0.25
0.50
0.75
1.00
18 12 3 0
29 29 8 0
Number at risk
0 50 100 150
Analysis time
0.00
0.25
0.50
0.75
1.00
68 34 9 1 1
47 45 14 0 0
Number at risk
0 50 100 150 200
Analysis time
0.00
0.25
0.50
0.75
1.00
50 22 6 1 1
18 16 6 0 0
Number at risk
0 50 100 150 200
Analysis time
Low-risk signature
High-risk signature
Low-risk signature
High-risk signature
Low-risk signature
High-risk signature
P<0.0001 P=0.0007 P=0.0008
F G H Low-risk patients – 90% sensitivity
cut-off value
High-risk patients – 90% sensitivity
cut-off value
All patients – 90% sensitivity
cut-off value
90% sensitivity
cut-off value
Pr
ob
ab
ilit
y 
of
pr
og
re
ss
io
n 
fre
e 
su
rv
iva
l
Pr
ob
ab
ilit
y 
of
pr
og
re
ss
io
n 
fre
e 
su
rv
iva
l
Pr
ob
ab
ilit
y 
of
pr
og
re
ss
io
n 
fre
e 
su
rv
iva
l
Pr
ob
ab
ilit
y 
of
pr
og
re
ss
io
n 
fre
e 
su
rv
iva
l
Pr
ob
ab
ilit
y 
of
pr
og
re
ss
io
n 
fre
e 
su
rv
iva
l
Pr
ob
ab
ilit
y 
of
pr
og
re
ss
io
n 
fre
e 
su
rv
iva
l
Progression signatureNo progression signature
Figure 1 The 12-gene PCR signature for predicting disease progression. (A) Expression patterns of the 12 genes in the 115 tumour samples analysed.
The upper seven genes are upregulated in progressing tumours and the lower five genes are downregulated in progressing tumours. Yellow, upregulation of
the gene; blue, downregulation; and black, median expression. The vertical red line separates tumours classified with the progression signature (right) from
tumours with the non-progression signature (left) based on the optimal cut-off value. The black boxes below the heat map denote progressing tumours,
stage T1 tumours and high-grade tumours. (B) ROC curve for the 12-gene signature values (average Ct (genes downregulated in progressing
tumours) average Ct (genes upregulated in progressing tumours)). The value with the highest accuracy is indicated as the optimal cut-off value for the
dichotomised test (used in C, D and E), and the 90% sensitivity value is indicated (used in F, G and H). (C, F) Kaplan–Meier plots of progression-free
survival as a function of the 12-gene PCR signature. All 115 patients are included in the analysis. (D, G) Kaplan–Meier plots of progression-free survival as a
function of the 12-gene PCR signature when including high-risk patients only (stage T1 or high grade or CIS). (E, H) Kaplan–Meier plots of progression-free
survival as a function of the 12-gene PCR signature when including low-risk patients only.
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The monoclonal and oligoclonal nature of bladder tumours has
been observed in several previous reports (Hartmann et al, 2000;
Zieger et al, 2005). Sometimes the latest removed tumour was
classified as high risk – sometimes it was the first removed tumour.
This seems controversial; however, previous publications have
indicated that the order of tumour resection may not be the order
of formation of the tumour in the bladder. Very early tumours that
grow very slowly may be resected later than offspring from this
tumour that has a more rapid proliferation (van Tilborg et al,
2000). Whether a switch in clonality is reflected at cystoscopic
examination is at present unknown, but could be triggering a new
molecular analysis. The analysis of intra-patient, and probably
intra-tumour, variation of molecular signatures may be highly
relevant in other cancer diseases with synchronous multifocal
presentation like, for example, breast and prostate cancer.
Importantly, most of the samples used in this study to delineate
the 12-gene PCR signature were analysed in the previous micro-
array-based validation study also, and consequently this study is to
a large degree a technology-transfer study, and not a true validat-
ion of the molecular signature. Therefore, the relatively high HRs
reported here for the 12-gene signature are based on the optimal
cut-off values, and hence represent best case values, and the
proposed 12-gene signature needs external validation before
eventual clinical implementation. Furthermore, the technical
reproducibility of the 12-gene signature needs to be further
studied; however, because there is no need for normalisation
genes, the assay and associated statistical calculations are easily
handled.
The population studied here is neither consecutive nor included
within a certain time interval, and consequently different biases
may have been introduced; different follow-up guidelines and
treatment regimens have been applied in different countries and in
different time periods (e.g., a large fraction of high-risk patients
have not received adjuvant treatment, and diagnosis of CIS from
selected site biopsies has not been performed routinely).
Furthermore, few women were included and several parameters
regarding, for example, smoking history were not available.
Therefore, prospective studies are needed for further validation
of the findings. To address this, we are currently validating the
12-gene signature in an ongoing prospective study that will
ultimately include 1200 patients with bladder cancer (UROMOL,
FP7 EU project).
The 12-gene signature selected in this work includes six novel
prognostic markers not included in previously reported signatures
from our group. UBE2C and COL18A1 have been identified earlier
in another meta-analysis of bladder cancer gene-expression data
(Oncomine). The UBE2C and COL18A1 expression was described
as being upregulated in progressing tumours and both genes were
included in a 57-gene qRT–PCR signature (Wang et al, 2009).
SKAP2 has not been described in bladder cancer, but was earlier
identified as having pro-invasion activities in human melanoma cells
Table 4 Progression-associated genes selected for the final 12-gene PCR
signature and associated statistics based on 115 tumour samples
Cox regression
analysis
GENE
Pearson’s
correlationa
Wilcoxon
signed-rank test
P-value
Beta
coefficient P-value
ROC
AUC
CDC25B  0.268 0.004  0.605 0.002 0.665
KPNA2  0.234 0.004  0.490 0.006 0.663
BIRC5  0.251 0.004  0.449 0.005 0.667
COL18A1  0.307 o0.001  0.368 0.002 0.704
MSN  0.277 o0.001  0.328 0.007 0.690
UBE2C  0.331 o0.001  0.315 o0.001 0.729
COL4A1  0.345 o0.001  0.300 o0.001 0.740
FABP4 0.374 o0.001 0.193 o0.001 0.729
MBNL2 0.297 o0.001 0.459 0.001 0.707
SKAP2 0.270 0.004 0.566 0.004 0.664
COL4A3BP 0.359 o0.001 0.777 o0.001 0.746
NEK1 0.253 0.003 0.804 0.003 0.671
Abbreviations: AUC¼ area under curve; ROC¼ receiver operating characteristic.
aPo0.01 if the Pearson’s correlation is 40.176 or o 0.176. A negative value
denotes genes upregulated in progressing tumours.
Gene signatures:
38 genes selected
Microarray data:
58 genes selected
96 genes selected
Primer design:
validation of primer
sensitivity and specificity 
35 genes selected :
qRT-PCR  using
115 samples
Final 12 genes
selected
Figure 2 Schematic overview of steps involved in delineation of the final
12-gene PCR signature.
Table 5 Univariate and multivariate Cox regression analysis of progression-free survival
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age (per 5 year increment) 1.21 (1.02–1.43) 0.024 1.02 (0.85–1.23) 0.806
Sex (men vs women) 0.62 (0.31–1.25) 0.184
Stage (T1 vs Ta) 4.07 (2.13–7.77) o0.001 1.64 (0.63–4.28) 0.311
Grade (high vs lowþ PUNLMP) 4.82 (2.25–10.34) o0.001 1.25 (0.41–3.86) 0.703
Concomitant CISa (presence vs absence) 2.37 (1.06–5.30) 0.035
Treatment (BCG and MMC vs no treatment) 0.23 (0.09–0.58) 0.002 0.20 (0.07–0.57) 0.003
12-gene PCR signature (high risk vs low risk) 9.36 (4.66–18.81) o0.001 8.30 (3.66–18.84) o0.001
Abbreviations: BCG¼ bacillus Calmette-Guerin; CI¼ confidence interval; CIS¼ concurrent carcinoma in situ; MMC¼mitomycin C. aCIS status was only known for 69 patients
and consequently not included in the multivariate analysis. Bold indicates significant P-values (Po0.05).
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(Kabbarah et al, 2010). NEK1 expression was identified in this study
to be downregulated in progressing tumours compared with non-
progressing tumours. Recently, this molecule has been shown to be
involved in maintenance of chromosomal stability, and dysregula-
tion of the molecule was associated with chromosomal instability
(Chen et al, 2011). COL4A3BP expression has been found increased
in drug-resistant cell lines, and it has been suggested to be a target
for chemotherapy-resistant cancers (Swanton et al, 2007).
In conclusion, we have delineated a PCR-based 12-gene
signature for disease progression in patients with non-muscle
invasive bladder cancer. Based on molecular analysis of intra-
patient variation, we suggest that this PCR-based test should be
applied to tumours from all patient visits in order to increase test
sensitivity.
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